Cardiol Therapeutics Inc. (CRDL) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Cardiol Therapeutics Inc. (CRDL) closed at USD 1.14 on 2026-10-14, a change of -2.6 % over the past year, with a market capitalization of USD 139.74M.

Cardiol Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Cardiol Therapeutics Inc. key figures

Previous close

USD 1.14 (2026-10-14)

1-year change

-2.6 %

Market cap

USD 139.74M

Enterprise value

USD 108.37M

P/E ratio (trailing)

-4.79

P/E ratio (forward)

-5.00

EPS (trailing)

-0.24

EPS (forward)

-0.23

PEG ratio

n/a

Price to book

7.90

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.51

Employees

18

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Cardiol Therapeutics Inc. and compare it with other stocks.